Pacific Biosciences of California (PACB) to Release Quarterly Earnings on Thursday

Pacific Biosciences of California (NASDAQ:PACB) is anticipated to issue its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $39.95 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. Pacific Biosciences of California had a negative net margin of 341.47% and a negative return on equity of 326.43%. The firm had revenue of $44.65 million during the quarter, compared to analysts’ expectations of $44.60 million. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Pacific Biosciences of California Price Performance

Shares of PACB opened at $1.55 on Tuesday. Pacific Biosciences of California has a 1-year low of $0.85 and a 1-year high of $2.73. The stock has a market cap of $481.26 million, a PE ratio of -0.84 and a beta of 2.40. The company has a debt-to-equity ratio of 120.65, a current ratio of 5.15 and a quick ratio of 4.47. The firm has a fifty day moving average price of $1.48 and a 200 day moving average price of $1.84.

Insider Activity

In other news, insider Oene Mark Van sold 55,107 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.63, for a total transaction of $89,824.41. Following the transaction, the insider directly owned 1,742,638 shares in the company, valued at $2,840,499.94. The trade was a 3.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michele Farmer sold 35,215 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $1.58, for a total transaction of $55,639.70. Following the transaction, the insider owned 234,044 shares in the company, valued at approximately $369,789.52. This trade represents a 13.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 729,711 shares of company stock valued at $1,161,951. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PACB. ARK Investment Management LLC increased its stake in shares of Pacific Biosciences of California by 20.5% during the fourth quarter. ARK Investment Management LLC now owns 37,264,228 shares of the biotechnology company’s stock worth $69,684,000 after acquiring an additional 6,340,125 shares during the period. Millennium Management LLC increased its stake in shares of Pacific Biosciences of California by 500.9% during the third quarter. Millennium Management LLC now owns 4,916,795 shares of the biotechnology company’s stock worth $6,293,000 after acquiring an additional 4,098,555 shares during the period. Renaissance Technologies LLC purchased a new stake in Pacific Biosciences of California during the fourth quarter worth about $7,201,000. HRT Financial LP acquired a new position in Pacific Biosciences of California during the fourth quarter worth about $2,549,000. Finally, Goldman Sachs Group Inc. increased its holdings in Pacific Biosciences of California by 170.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,378,872 shares of the biotechnology company’s stock valued at $2,578,000 after buying an additional 869,445 shares in the last quarter.

Analyst Ratings Changes

PACB has been the subject of a number of research reports. Barclays reduced their price target on shares of Pacific Biosciences of California from $1.50 to $1.00 and set an “underweight” rating for the company in a research report on Tuesday, April 14th. Zacks Research cut shares of Pacific Biosciences of California from a “strong-buy” rating to a “hold” rating in a report on Monday, April 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pacific Biosciences of California in a report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $1.67.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.